Online citations, reference lists, and bibliographies.
← Back to Search

Synergistic Antitumor Activity Of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) In Combination With Carboplatin And Pemetrexed In Malignant Pleural Mesothelioma

G. Pasello, L. Urso, M. Silic-Benussi, M. Schiavon, I. Cavallari, G. Marulli, N. Nannini, F. Rea, V. Ciminale, A. Favaretto
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: Malignant pleural mesothelioma (MPM) is an aggressive, currently incurable tumor with increasing incidence in industrialized countries. Tumor necrosis factor-related, apoptosis-inducing ligand (TRAIL) is a member of the TNF family, which induces cancer cell death through extrinsic apoptotic pathway, while sparing normal cells. The aim of this study was to investigate the antitumor activity of recombinant human Apo2L/TRAIL (dulanermin) in combination with chemotherapy in MPM in vitro and in vivo. Methods: In the present studies, we employed a panel of MPM cell lines to test the antitumor activity of recombinant human Apo2L/TRAIL (T) in combination with carboplatin and pemetrexed (CP) in vitro and SCID mice. Results: Results demonstrated a significant increase of apoptosis in cell lines treated with CPT compared with those receiving CP or T as single agents. This synergistic effect was dependent on the ability of CP to increase the expression of the TRAIL receptors DR4 and DR5 in a p53 manner. The CPT combination was also effective in blocking the growth of MPM cell lines in a SCID mice preclinical model. Conclusions: CPT increases MPM cell death in vitro and in vivo compared with CP. In vitro results suggest that chemotherapy sensitizes MPM to TRAIL-dependent apoptosis through p53 activation and subsequent upregulation of DRs.
This paper references
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
M. Nagane (2000)
10.1200/JCO.2011.37.2623
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
J. Soria (2011)
10.1016/S0960-9822(06)00422-2
A novel receptor for Apo2L/TRAIL contains a truncated death domain
S. Marsters (1997)
10.1038/nrc821
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A. Ashkenazi (2002)
10.1016/J.EJCA.2006.03.018
The clinical trail of TRAIL.
E. Duiker (2006)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Next generation sequencing in malignant pleural mesothelioma: preliminary data from a retrospective cohort of 123 patients
NS LoIaconoMarco (2013)
10.1074/JBC.M106643200
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53*
W. H. Hoffman (2002)
HGS - ETR 1 , a fully human TRAIL - receptor 1 monoclonal antibody , induces cell death in multiple tumour types in vitro and in vivo
L Pukac (2005)
10.1111/j.1365-2141.2005.05656.x
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell death
G. Georgakis (2005)
10.1200/JCO.2009.25.1991
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
R. Herbst (2010)
10.1002/cncr.23337
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
10.1016/j.lungcan.2011.01.005
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
G. Pasello (2011)
New insights into apoptosis signaling by Apo 2 L / TRAIL
F Gonzalvez (2010)
10.1126/SCIENCE.277.5327.815
An antagonist decoy receptor and a death domain-containing receptor for TRAIL.
G. Pan (1997)
10.1016/S0301-472X(01)00677-4
Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines.
Q. Liu (2001)
10.1158/0008-5472.CAN-04-0408
Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival
H. Jin (2004)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
10.1074/JBC.271.22.12687
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*
R. Pitti (1996)
10.1165/AJRCMB.16.1.8998073
Absence of p53 mutations in malignant mesotheliomas.
O. Mor (1997)
10.1074/jbc.273.23.14363
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL*
J. G. Emery (1998)
10.1165/RCMB.2004-0355OC
A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance.
Ki-Up Kim (2005)
10.1200/JCO.2009.25.4847
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.
J. Soria (2010)
10.1016/j.ctrv.2012.03.001
An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.
G. Pasello (2013)
Gruppo di lavoro ReNaM. [Epidemiological surveillance of malignant mesothelioma cases in Italy: incidence and asbestos exposure figures by the Italian mesothelioma registry
A Marinaccio
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1038/onc.2010.221
New insights into apoptosis signaling by Apo2L/TRAIL
F. Gonzálvez (2010)
10.1186/1476-4598-6-66
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
L. Belyanskaya (2007)
10.1186/1745-6673-3-34
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
A. Xanthopoulos (2008)
10.1126/SCIENCE.277.5327.818
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.
J. Sheridan (1997)
Targeting p 53 as a therapeutic strategy in sensitizing TRAIL - induced apoptosis in cancer cells
J Zhao (2012)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1126/SCIENCE.277.5327.768
How TRAIL Kills Cancer Cells, But Not Normal Cells
T. Gura (1997)
10.1186/1471-2407-13-140
TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages
Bao-Zhu Yuan (2012)
10.2486/INDHEALTH.45.379
Malignant mesothelioma: global incidence and relationship with asbestos.
C. Bianchi (2007)
10.1038/sj.bjc.6602487
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
L. Pukac (2005)
[Epidemiological surveillance of malignant mesothelioma cases in Italy: incidence and asbestos exposure figures by the Italian mesothelioma registry (ReNaM)].
A. Marinaccio (2007)
10.1128/MCB.20.1.205-212.2000
Increased Expression of Death Receptors 4 and 5 Synergizes the Apoptosis Response to Combined Treatment with Etoposide and TRAIL
S. Gibson (2000)
10.1186/1479-5876-3-22
The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
B. Hylander (2005)
10.1172/JCI6926
Safety and antitumor activity of recombinant soluble Apo2 ligand.
A. Ashkenazi (1999)
10.1038/sj.cdd.4401187
Apo2L/TRAIL and its death and decoy receptors
H N LeBlanc (2003)
Phase II study of peme - trexed plus carboplatin in malignant pleural mesothelioma
GL Ceresoli (2006)
Phase III study of peme - trexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang (2003)
Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
S. Kelley (2001)
10.1038/sj.bjc.6601707
α-Tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells
M. Tomasetti (2004)
10.1002/cncr.22552
Update on the molecular biology of malignant mesothelioma
A. Lee (2007)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1126/SCIENCE.276.5309.111
The Receptor for the Cytotoxic Ligand TRAIL
G. Pan (1997)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1016/j.canlet.2011.09.040
Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells.
Jing Zhao (2012)
10.1158/1535-7163.MCT-07-0278
Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim
Keith S. Abayasiriwardana (2007)
10.1038/sj.onc.1208051
FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells
Maria Rita Rippo (2004)
10.1200/JCO.2007.15.7198
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
A. Ashkenazi (2008)
Additive effect of Apo 2 L / TRAIL and Adeno - p 53 in the induction of apoptosis in myeloma cell lines
Q Liu (2001)
Scagliotti Giorgio V. Next generation sequencing in malignant pleural mesothelioma: preliminary data from a retrospective cohort of 123 patients
N S Lo Iacono Marco (2013)
10.1007/s10928-012-9269-x
Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab
B. Kay (2012)
10.1073/PNAS.030545097
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy.
A. Chinnaiyan (2000)
10.1097/JTO.0b013e318194f991
A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL
J. Symanowski (2009)
Phase I dose - escalation study of recombinant human Apo 2 L / TRAIL , a dual proapoptotic receptor agonist , in patients with advanced cancer
RS Herbst (2010)
Retreatment with peme - trexed - based chemotherapy in patients with malignant pleural mesothelioma
GL Ceresoli (2011)
10.1038/sj.cgt.7700792
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
L. Zhang (2005)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar